Table 2.
Studies investigating PRS to predict GDM/T2D, or glycemic traits during pregnancy
First author | Year | Ancestry | Outcome | Sample size (case/control) | Number of variants | Variant selection for PS | Method of PS | Risk of outcome by PS | Other findings |
---|---|---|---|---|---|---|---|---|---|
Moen GH | 2018 | European | Fasting Glucose | 529 | 33 | FG variants | Weighted PS | NA | GRS explained 4.95% of variance of FG GW 14–16 |
Powe CE | 2018 | European | Fasting Glucose (Gen3G) | 551 | 38 | FG variants | Weighted PS | 0.39 (0.27–0.51) per unit increase | GRS explained 7% of variance of FG |
Powe CE | 2018 | European | Fasting Glucose (HAPO) | 1380 | 38 | FG variants | Weighted PS | 0.42 (0.06–0.18) per unit increase | GRS explained 7% of variance of FG |
Lauenborg J | 2008 | European | GDM | 2127 (244/1883) | 11 | T2D variants | Weighted PS | 1.18 (1.10–1.27) per unit increase | AUC ROC clinical 0.62; AUC ROC clinical + PS 0.68 |
Sullivan SD | 2014 | Multi-ethnic | GDM | 1383 (281/1102) | 34 | T2D variants | Weighted PS | 1.05 (1.00–1.08) per unit increase | |
Comrier H | 2015 | European | GDM | 296 (214/82) | 36 | T2D variants | Explained-variance PS | NA | Significantly higher PS in cases vs controls (1.21 ± 0.18 vs 1.17 ±0.15, P< 0.0001) |
Kawai VK | 2017 | European | GDM | 1996 (458/1538) | 34 | T2D or FG variants | Weighted PS | 1.11 (1.08–1.14) per unit increase | AUC ROC clinical 0.67; AUC ROC clinical + PS 0.70 |
Ding M | 2018 | European | GDM | 8722 (2636/6086) | 11 | T2D variants | Weighted PS | 1.04 (1.03–1.05) per unit increase | |
Powe CE | 2018 | European | GDM (Gen3G) | 551 (43/508) | 85 | T2D variants | Weighted PS | 1.06 (1.01–1.10) per unit increase | |
Powe CE | 2018 | European | GDM (HAPO) | 1380 (207/1173) | 85 | T2D variants | Weighted PS | 1.03 (1.01–1.06) per unit increase | |
Ekelund M | 2012 | Multi-ethnic | T2D | 637 (134/503) | 13 | T2D variants | Weighted PS | 1.11 (1.05–1.18) per unit increase | |
KwakSH | 2013 | East Asian | T2D | 395 (116/279) | 48 | T2D variants | Weighted PS | 1.66 (1.30–2.13) per unit increase | AUC ROC clinical 0.74; AUC ROC clinical + PS 0.78 |
Comrier H | 2015 | European | T2D/Prediabetes | 214 (135/79) | 36 | T2D variants | Explained-variance | NA | AUC ROC clinical 0.63; AUC ROC clinical + PS 0.67 |
LiM | 2020 | European | T2D | 2434 (601/1833) | 59 | T2D or FG variants | Unweighted PS | 1.07(1.01–1.14) per 5 risk alleles | |
AUC, area under the curve; FG, fasting glucose; GW, gestational week; NA, not available; PS, polygenic score; ROC, receiver operating characteristics; T2D, type 2 diabetes